Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Lumbar Degenerative Spondylolisthesis Treatment Study

Clinical Trial Title: 
A concurrently controlled study of LimiFlex™ Paraspinous Tension Band in the treatment of lumbar degenerative spondylolisthesis with spinal stenosis.
Clinical Trial Protocol ID: 
17021501
Clinical Trial Investigator Name: 
Harel Deutsch, MD
Clinical Trial Protocol Description: 

The LimiFlex™ Clinical Trial is a prospective, concurrently controlled, multi-center study to evaluate the safety and effectiveness of decompression and stabilization with the Empirical Spine LimiFlex™ Paraspinous Tension Band compared to decompression and transforaminal lumbar interbody fusion (TLIF) with concomitant posterolateral fusion (PLF) for the treatment of lumbar degenerative spondylolisthesis (Grade I per Meyerding classification) with spinal stenosis. Clinical trial sites will enroll solely LimiFlex subjects or solely TLIF/PLF subjects.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have lumbar degenerative spondylolisthesis (Grade I per Meyerding classification), at one level from L1 to S1, with radiographic confirmation using X-ray.
    • Grade I spondylolisthesis per Meyerding classification includes up to 25% anterior translation of a vertebra relative to the superior endplate of the subjacent vertebra at the index level. A patient is considered to have spondylolisthesis with a minimum 10% anterolisthesis at the affected level in a lateral x-ray image.
  • Have lumbar spinal stenosis, at the level diagnosed with degenerative spondylolisthesis, and confirmed radiographically using CT or MRI.
    • At the index level, lumbar spinal stenosis is at least moderate lumbar canal stenosis, defined as more than 25% reduction of the cross-sectional area compared with the next adjacent normal level, with nerve root crowding compared with the normal level, as determined by the investigator on CT Scan or MRI.
  • Have neurogenic claudication or radiculopathic symptoms including leg pain, muscle weakness, and/or sensation abnormality, with or without back pain as evidenced by patient history.
  • Have persistent symptoms despite at least 6 months of conservative treatment that may include but is not limited to physical therapy, medications, and/or epidural injections.

You will be excluded from the study if any of the following criteria apply to you:

  • Have a primary and predominate diagnosis of discogenic back pain.
  • Have a primary and predominate diagnosis of facet-mediated back pain.
  • Have back or non-radicular leg pain of unknown etiology.
  • Have significant peripheral vascular disease causing vascular claudication

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Spine and Back Disorders
Contact Phone: 
(312) 942-8681
Contact Name: 
Chris Keegan